Emerging markets are broadly defined as nations in the process of rapid growth and industrialization. Taking a look in to the trends of the most significant of these markets namely Brazil, Russia. India, China and South Korea, or more commonly known as BRICS markets, certain interesting trends emerge. Over the past 10 years, unsurprisingly, the majority of products launched within BRICS markets were small molecules while biosimilar products accounted for less than 1% of total products launched. Small molecules still dominate R&D focus with over 800 in BRICS pipeline, however biosimilars are now the second most  numberable pipeline product type.

Development of biosimilars has surged in prominence in comparison to the product types launched of the last 10 years, as the percentage of biosimilar products in each region’s pipeline has increased substantially. In Brazil, 23% of pipeline products are biosimilar the majority of which are monoclonal antibodies. In Russia biosimilars account for 35% of products in development, the majority of which are recombinant proteins. Biosimilars account for 26% of pipeline products in India with the focus on recombinant proteins while in China and South Korea they only account for 8 and 6% respectively. Recombinant protein biosimilar pipeline products are slightly greater in number than monoclonal antibody in China while in South Korea monoclonal antibody is more than double that of recombinant proteins.

BRICS Pipeline Product Type Breakdown